Canaccord Genuity Group Forecasts Veru Q3 Earnings

Veru Inc. (NASDAQ:VERU) – Research analysts at Canaccord Genuity Group issued their Q3 2026 earnings estimates for Veru in a report issued on Thursday, August 6th. Canaccord Genuity Group analyst E. Nash expects that the company will post earnings per share of ($0.30) for the quarter. Canaccord Genuity Group has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Veru’s current full-year earnings is ($1.07) per share.

Veru (NASDAQ:VERU) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02.

Several other brokerages have also commented on VERU. Wall Street Zen raised Veru to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings upgraded Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Finally, Oppenheimer cut their price objective on Veru from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

Veru Trading Up 0.7%

Shares of VERU opened at $2.79 on Monday. The stock has a market cap of $44.78 million, a PE ratio of -3.13 and a beta of -1.15. Veru has a 1 year low of $2.05 and a 1 year high of $7.33. The stock has a 50 day simple moving average of $2.73 and a 200-day simple moving average of $2.50.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in Veru by 69.3% in the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after acquiring an additional 5,008 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in Veru by 3.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 197,876 shares of the company’s stock worth $423,000 after purchasing an additional 5,708 shares during the period. Bank of America Corp DE raised its holdings in Veru by 5.5% during the 2nd quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock worth $108,000 after purchasing an additional 9,637 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in Veru during the 3rd quarter worth about $38,000. Finally, Blair William & Co. IL lifted its position in Veru by 26.3% during the 4th quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.